First Time Loading...

Lyell Immunopharma Inc
NASDAQ:LYEL

Watchlist Manager
Lyell Immunopharma Inc Logo
Lyell Immunopharma Inc
NASDAQ:LYEL
Watchlist
Price: 2.36 USD -1.67% Market Closed
Updated: May 4, 2024

Income Statement

Earnings Waterfall
Lyell Immunopharma Inc

Revenue
130k USD
Operating Expenses
-247.1m USD
Operating Income
-247m USD
Other Expenses
12.4m USD
Net Income
-234.6m USD

Income Statement
Lyell Immunopharma Inc

Rotate your device to view
Income Statement
Currency: USD
Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023
Revenue
Revenue
8
N/A
9
+15%
8
-5%
10
+20%
11
+5%
9
-18%
42
+378%
39
-7%
85
+117%
84
-1%
48
-42%
49
+0%
0
-100%
Operating Income
Operating Expenses
(220)
(243)
(203)
(217)
(225)
(273)
(281)
(259)
(272)
(265)
(258)
(251)
(247)
Selling, General & Administrative
(47)
(55)
(64)
(72)
(89)
(107)
(118)
(123)
(117)
(102)
(91)
(80)
(67)
Research & Development
(182)
(198)
(148)
(155)
(135)
(137)
(131)
(138)
(164)
(171)
(178)
(183)
(186)
Other Operating Expenses
9
10
9
10
(1)
(30)
(32)
2
10
8
11
12
6
Operating Income
(212)
N/A
(234)
-11%
(194)
+17%
(207)
-6%
(214)
-4%
(264)
-23%
(239)
+10%
(220)
+8%
(187)
+15%
(181)
+3%
(210)
-16%
(202)
+4%
(247)
-22%
Pre-Tax Income
Interest Income Expense
6
4
2
1
1
1
2
3
6
10
14
20
23
Non-Reccuring Items
0
0
0
0
(37)
0
0
(41)
(5)
(15)
(18)
(13)
(13)
Total Other Income
2
0
(0)
(0)
0
(0)
0
(0)
3
4
4
5
2
Pre-Tax Income
(204)
N/A
(230)
-13%
(192)
+17%
(205)
-7%
(250)
-22%
(263)
-5%
(237)
+10%
(258)
-9%
(183)
+29%
(182)
+1%
(210)
-15%
(190)
+9%
(235)
-23%
Net Income
Income from Continuing Operations
(204)
(230)
(192)
(205)
(250)
(263)
(237)
(258)
(183)
(182)
(210)
(190)
(235)
Net Income (Common)
(204)
N/A
(230)
-13%
(192)
+17%
(205)
-7%
(250)
-22%
(263)
-5%
(237)
+10%
(258)
-9%
(183)
+29%
(182)
+1%
(210)
-15%
(190)
+9%
(235)
-23%
EPS (Diluted)
-0.84
N/A
-0.95
-13%
-0.8
+16%
-0.85
-6%
-1.03
-21%
-1.07
-4%
-0.96
+10%
-1.04
-8%
-0.73
+30%
-0.73
N/A
-0.84
-15%
-0.76
+10%
-0.93
-22%

See Also

Discover More